Company intelligence / Profile preview

Prestigio

Ownership: Private
Development stage: Other

Overview

Prestige Biopharma has developed a pipeline of biosimilars and novel monoclonal antibodies targeting unmet medical needs such as pancreatic cancer. They also have next-generation vaccines under development. Their biosimilar portfolio aims to provide cost-effective alternatives to existing biologic therapies, while their innovative antibody programs target first-in-class mechanisms. Clinical results are not detailed publicly, but the company claims rapid advancement toward global commercialization with several programs at various clinical stages

Therapeutic areas: Critical CareOncologyInfectious Diseases
Modalities: Monoclonal antibodyBiosimilarVaccine
Industry: Biotech

Partnerships

Collaborations with global pharmaceutical companies mentioned but not specifically named in public sources

Beyond the preview

Go deeper on Prestigio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prestigio.

Explore the full profile